Golivertx is a pioneering brand specializing in the development of Innovative Therapy Medications (ITMs) for liver regenerative medicine. As a spin-off of CRTI UMR1064, ITUN, CHU de Nantes, Golivertx is at the forefront of cutting-edge biomedical innovation. Their aim is to provide alternative solutions to liver transplantation, which carries risks and limitations.

Golivertx is focused on developing a new generation of Medication Therapies using pluripotent stem cells. These cells have the potential to regenerate and repair damaged or diseased organs and tissues. With their team of experts and state-of-the-art facilities, Golivertx is working towards manufacturing these therapeutic medications on an industrial scale, making them accessible for patients in need.

By harnessing the power of regenerative medicine, Golivertx is poised to become a major player in the future of liver regeneration and the healthcare industry